FDA Turns Up the Heat on GLP 1 Dupes Sold ​“For Research Use Only,” Finds Intended Use Suggests Otherwise

In this episode, we unpack the FDA’s latest enforcement wave targeting GLP-1 ​“dupes,” where companies have been marketing unapproved injectable products as ​“research use only” or ​“not for human consumption,” while simultaneously providing dosing instructions, testimonials, and other signals of intended human use. The FDA’s message is increasingly clear: it will look beyond disclaimers and focus on how products are actually marketed and used, treating misleading labeling as a potential violation of drug laws and a serious public health risk as scrutiny of compounded and unapproved GLP-1 products continues to intensify.

Hosted by Simone Roach. Based on a blog post by Donnelly L. McDowell and Cristina Ferretti.